Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences - 18 Aug 2022

Qin C P, Song Y X, Ding M T, Wang F, Lin J X, Yang W B, DU Y Q, Li Q, Liu S J, Xu T

Abstract excerpt

OBJECTIVE: To establish a mutation prediction model for efficacy assessment, the genomic sequencing data of renal cancer patients from the MSKCC (Memorial Sloan Kettering Cancer Center) pan-cancer immunotherapy cohort was used. METHODS: The genomic sequencing data of 121 clear cell renal cell carcinoma patients treated with immune checkpoint inhibitors (ICI) in the MSKCC pan-cancer immunotherapy cohort were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Kidney Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35950389
PMCID: PMC9385530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].PMID 35950389Read ↗

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancersSemantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesSemantic proximity Read ↗

DNA methylation is a key determinant of response to targeted and immune checkpoint therapies in metastatic renal cell carcinomaSemantic proximity Read ↗

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Semantic proximity Read ↗

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma.Semantic proximity Read ↗

Treatment strategies for clear cell renal cell carcinoma: Past, present and futureSemantic proximity Read ↗

A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1Semantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer TypesSemantic proximity Read ↗

An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.